AMSTERDAM, The Netherlands, January 31, 2011 - Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Union (EU) has finalized a EUR 3.3 million grant to the AIPGENE consortium, of which AMT is a member, for the development of a gene therapy product for Acute Intermittent Porphyria (AIP). AIP is a severe and progressive disease caused by the inability of the body to produce the heme protein, a component of hemoglobin, as well as other important proteins.
A Unique Store Concept Right Next to the City's Most Famous Running Spot
Older News
S M T W T F S
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31 1 2 3 4 5
Copyright© 2011 The Gaea Times